

Pharmaceuticals Market - 2024-2033

<https://marketpublishers.com/r/P6DE6028742EEN.html>

Date: March 2026

Pages: 189

Price: US\$ 2,999.00 (Single User License)

ID: P6DE6028742EEN

Abstracts

The Pharmaceuticals Market was valued at US\$ 1.5 Trillion in 2024 and is anticipated to reach US\$ 2.5 Trillion by 2033, at a CAGR of 0.058 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Pharmaceuticals Market.

This report delivers a comprehensive overview of the Pharmaceuticals Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pharmaceuticals Market. The Pharmaceuticals Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Pharmaceuticals Market Scope:

By Molecule Type / Product Modality

Small Molecules (Conventional Drugs)

Large Molecules (Biologics)

Biosimilars

Advanced Therapies

By Product Type

Branded

Generics

By Prescription Type

Prescription

Over-the-Counter

By Therapeutic Area / Disease Class

Oncology

Cardiovascular Diseases

Metabolic Diseases

Immunology & Autoimmune Diseases

Infectious Diseases

Neurology

Mental Health Disorders (Psychiatry)

Respiratory Diseases

Gastrointestinal Disorders

Women's Health Diseases

Men's Health / Urology

Dermatological Conditions

Ophthalmology (Eye Conditions)

Hematological Disorders

Endocrine Disorders

Renal Diseases

Liver Conditions

Musculoskeletal Disorders / Pain Management

Allergy & Immunology (Allergies)

Genetic & Rare Diseases (Orphan)

Dental / Oral Health (optional)

Others

By Route of Administration

Oral

Parenteral

Topical / Dermal

Inhalation

Ophthalmic

Transdermal

Rectal

Vaginal

Buccal / Sublingual

Intrathecal / CNS Delivery (niche)

Others

By Dosage Form

Tablets

Capsules

Powders / Granules

Liquids

Injectables

Inhalers

Topicals

Drops (Ophthalmic/Otic)

Suppositories

Sprays (Nasal/Oral)

Implants (niche)

Others

By Age Group

Children & Adolescents

Adults

Geriatric

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy / E-Pharmacy

Specialty Pharmacy

Clinic Pharmacy / Physician Dispensing

Government / Public Procurement & Tenders

Wholesalers & Distributors

Others

By Care Setting

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Homecare / Self-Administration

Long-Term Care Facilities / Nursing Homes

Diagnostic Centers

Others

Key Players

Johnson & Johnson (J&J)

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

Pfizer Inc.

AbbVie Inc.

AstraZeneca

Novartis AG

Bristol-Myers Squibb Company

Lilly USA, LLC

Sanofi

Novo Nordisk A/S

GSK plc

Amgen Inc.

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim International GmbH

Gilead Sciences, Inc.

Bayer AG

Merck KGaA

Teva Pharmaceutical Industries Ltd.

Daiichi Sankyo Company, Ltd.

Biogen

Major Highlights

This report delivers a comprehensive overview of the Pharmaceuticals Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pharmaceuticals Market. The Pharmaceuticals Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Data
 - 1.1.1. Secondary Data
 - 1.1.2. Primary Data
 - 1.1.3. CAGR Analysis
- 1.2. Market Size Estimation Methodology
 - 1.2.1. Bottom-Up Approach
 - 1.2.2. Top-Down Approach
- 1.3. Market Breakdown & Data Triangulation
- 1.4. Research Assumptions
- 1.5. Limitations

2. DEFINITION AND OVERVIEW

- 2.1. Study Objectives
- 2.2. Market Definition
- 2.3. Market Scope
- 2.4. Stakeholder Analysis
- 2.5. Currency Considered
- 2.6. Study Period

3. EXECUTIVE SUMMARY

- 3.1. Key Takeaways
- 3.2. Top To Bottom Analysis
- 3.3. Market Share Analysis
- 3.4. Data Points from Key Primary Interviews
- 3.5. Data Points from Key Secondary Databases
- 3.6. Market Snapshot
- 3.7. Geographical Snapshot

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Changing food habits and sedentary lifestyle increase chronic and lifestyle

diseases

- 4.1.1.2. Government healthcare Medicare plans and policies
- 4.1.1.3. Increasing availability of generic medicines in developing countries
- 4.1.2. Restraints
 - 4.1.2.1. Patent expirations and generic competition (patent cliff)
 - 4.1.2.2. Limited access in developed countries, only on prescription
 - 4.1.2.3. Health risk and revenue losses due to counterfeit products
- 4.1.3. Impact Analysis – Drivers and Restraints
- 4.1.4. Opportunity
- 4.1.5. Challenges
- 4.1.6. Trends

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Political Factors
- 5.3. Social Factors
 - 5.3.1. Changing Consumer Trends
 - 5.3.2. Population Growth
 - 5.3.3. Demographic Shifts
- 5.4. Economic Factors
 - 5.4.1. Interest Rates
 - 5.4.2. Disposable Incomes
 - 5.4.3. Inflation
 - 5.4.4. GDP
 - 5.4.5. Exchange Rates
 - 5.4.6. Unemployment Rates
- 5.5. Geopolitical Factors
- 5.6. Supply/Value Chain Analysis
- 5.7. Pricing Analysis
- 5.8. Tariff Analysis
 - 5.8.1. Overview Of Relevant Tariffs
 - 5.8.2. Trade Policies Influencing the Market
 - 5.8.3. Cost Impact Factors
 - 5.8.4. Supply Chain Disruptions
- 5.9. Trade Analysis - Export-Import Scenario
- 5.10. Regulatory Analysis
- 5.11. Technology Landscape
- 5.12. Go-To-Market (GTM) Strategy

- 5.13. Innovation & R&D Trends
- 5.14. Sustainability and ESG Analysis
- 5.15. Key Strategic Initiatives
 - 5.15.1. Emerging Players and Startups
 - 5.15.2. Major Players
- 5.16. DMI Opinion

6. BY MOLECULE TYPE / PRODUCT MODALITY

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type / Product Modality
 - 6.1.2. Market Attractiveness Index, By Molecule Type / Product Modality
- 6.2. Small Molecules (Conventional Drugs)
 - 6.2.1. Branded Small Molecules
 - 6.2.2. Generic Small Molecules
- 6.3. Large Molecules (Biologics)
 - 6.3.1. Monoclonal Antibodies
 - 6.3.2. Recombinant Proteins & Peptides
 - 6.3.3. Vaccines
 - 6.3.4. Plasma-Derived Biologics
 - 6.3.5. Others
- 6.4. Biosimilars
 - 6.4.1. Biosimilar Monoclonal Antibodies
 - 6.4.2. Biosimilar Recombinant Proteins/Peptides
 - 6.4.3. Biosimilar Erythropoietins
 - 6.4.4. Biosimilar Insulins
 - 6.4.5. Biosimilar G-CSF
 - 6.4.6. Others
- 6.5. Advanced Therapies
 - 6.5.1. Cell Therapy
 - 6.5.2. Gene Therapy
 - 6.5.3. Tissue-Engineered Products
 - 6.5.4. Others

7. BY PRODUCT TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

- 7.1.2. Market Attractiveness Index, By Product Type
- 7.2. Branded
- 7.3. Generics

8. BY PRESCRIPTION TYPE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
 - 8.1.2. Market Attractiveness Index, By Prescription Type
- 8.2. Prescription
- 8.3. Over-the-Counter

9. BY THERAPEUTIC AREA / DISEASE CLASS

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area / Disease Class
 - 9.1.2. Market Attractiveness Index, By Therapeutic Area / Disease Class
- 9.2. Oncology
- 9.3. Cardiovascular Diseases
- 9.4. Metabolic Diseases
 - 9.4.1. Diabetes
 - 9.4.2. Obesity
 - 9.4.3. Dyslipidemia
- 9.5. Immunology & Autoimmune Diseases
- 9.6. Infectious Diseases
- 9.7. Neurology
- 9.8. Mental Health Disorders (Psychiatry)
- 9.9. Respiratory Diseases
- 9.10. Gastrointestinal Disorders
- 9.11. Women's Health Diseases
- 9.12. Men's Health / Urology
- 9.13. Dermatological Conditions
- 9.14. Ophthalmology (Eye Conditions)
- 9.15. Hematological Disorders
- 9.16. Endocrine Disorders
- 9.17. Renal Diseases
- 9.18. Liver Conditions
- 9.19. Musculoskeletal Disorders / Pain Management

- 9.20. Allergy & Immunology (Allergies)
- 9.21. Genetic & Rare Diseases (Orphan)
- 9.22. Dental / Oral Health (optional)
- 9.23. Others

10. BY ROUTE OF ADMINISTRATION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.1.2. Market Attractiveness Index, By Route of Administration
- 10.2. Oral
- 10.3. Parenteral
 - 10.3.1. Intravenous
 - 10.3.2. Intramuscular
 - 10.3.3. Subcutaneous
 - 10.3.4. Intradermal
- 10.4. Topical / Dermal
- 10.5. Inhalation
- 10.6. Ophthalmic
- 10.7. Transdermal
- 10.8. Rectal
- 10.9. Vaginal
- 10.10. Buccal / Sublingual
- 10.11. Intrathecal / CNS Delivery (niche)
- 10.12. Others

11. BY DOSAGE FORM

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
 - 11.1.2. Market Attractiveness Index, By Dosage Form
- 11.2. Tablets
- 11.3. Capsules
- 11.4. Powders / Granules
- 11.5. Liquids
 - 11.5.1. Syrups
 - 11.5.2. Suspensions
 - 11.5.3. Solutions

11.6. Injectables

11.6.1. Vials

11.6.2. Prefilled Syringes

11.6.3. Auto-injectors

11.7. Inhalers

11.7.1. Metered Dose Inhalers

11.7.2. Prefilled Syringes

11.7.3. Auto-injectors

11.8. Topicals

11.8.1. Creams

11.8.2. Ointments

11.8.3. Gels

11.8.4. Lotions

11.8.5. Patches

11.9. Drops (Ophthalmic/Otic)

11.10. Suppositories

11.11. Sprays (Nasal/Oral)

11.12. Implants (niche)

11.13. Others

12. BY AGE GROUP

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

12.1.2. Market Attractiveness Index, By Age Group

12.2. Children & Adolescents

12.3. Adults

12.4. Geriatric

13. BY DISTRIBUTION CHANNEL

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13.1.2. Market Attractiveness Index, By Distribution Channel

13.2. Hospital Pharmacy

13.3. Retail Pharmacy

13.4. Online Pharmacy / E-Pharmacy

13.5. Specialty Pharmacy

13.6. Clinic Pharmacy / Physician Dispensing

- 13.7. Government / Public Procurement & Tenders
- 13.8. Wholesalers & Distributors
- 13.9. Others

14. BY CARE SETTING

- 14.1. Introduction
 - 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting
 - 14.1.2. Market Attractiveness Index, By Care Setting
- 14.2. Hospitals
- 14.3. Specialty Clinics
- 14.4. Ambulatory Surgical Centers
- 14.5. Homecare / Self-Administration
- 14.6. Long-Term Care Facilities / Nursing Homes
- 14.7. Diagnostic Centers
- 14.8. Others

15. BY REGION

- 15.1. Introduction
 - 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 15.1.2. Market Attractiveness Index, By Region
- 15.2. North America
 - 15.2.1. Introduction
 - 15.2.2. Key Region-Specific Dynamics
 - 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type / Product Modality
 - 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
 - 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area / Disease Class
 - 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
 - 15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 15.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 15.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting
 - 15.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.2.12.1. U.S.

15.2.12.2. Canada

15.3. Latin America

15.3.1. Introduction

15.3.2. Key Region-Specific Dynamics

15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type /
Product Modality

15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type

15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area /
Disease Class

15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of
Administration

15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form

15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

15.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

15.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting

15.3.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

15.3.12.1. Brazil

15.3.12.2. Argentina

15.3.12.3. Mexico

15.3.12.4. Chile

15.3.12.5. Colombia

15.3.12.6. Peru

15.3.12.7. Rest of Latin America

15.4. Europe

15.4.1. Introduction

15.4.2. Key Region-Specific Dynamics

15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type /
Product Modality

15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type

15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area /
Disease Class

15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of
Administration

15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form

15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

15.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

15.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting

15.4.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 15.4.12.1. Germany
- 15.4.12.2. United Kingdom
- 15.4.12.3. France
- 15.4.12.4. Italy
- 15.4.12.5. Spain
- 15.4.12.6. Netherlands
- 15.4.12.7. Switzerland
- 15.4.12.8. Sweden
- 15.4.12.9. Norway
- 15.4.12.10. Denmark
- 15.4.12.11. Belgium
- 15.4.12.12. Poland
- 15.4.12.13. Austria
- 15.4.12.14. Ireland
- 15.4.12.15. Portugal
- 15.4.12.16. Greece
- 15.4.12.17. Finland
- 15.4.12.18. Rest of Europe

15.5. Asia-Pacific

- 15.5.1. Introduction
- 15.5.2. Key Region-Specific Dynamics
- 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type / Product Modality
- 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
- 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area / Disease Class

15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

- 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
- 15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 15.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting
- 15.5.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.5.12.1. China
 - 15.5.12.2. Japan
 - 15.5.12.3. India
 - 15.5.12.4. South Korea

- 15.5.12.5. Australia
- 15.5.12.6. New Zealand
- 15.5.12.7. Singapore
- 15.5.12.8. Malaysia
- 15.5.12.9. Thailand
- 15.5.12.10. Indonesia
- 15.5.12.11. Vietnam
- 15.5.12.12. Philippines
- 15.5.12.13. Taiwan
- 15.5.12.14. Rest of Asia Pacific

15.6. Middle East and Africa

- 15.6.1. Introduction
- 15.6.2. Key Region-Specific Dynamics
- 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule Type / Product Modality
- 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Prescription Type
- 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area / Disease Class
- 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
- 15.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 15.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.6.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Setting
- 15.6.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 15.6.12.1. Saudi Arabia
 - 15.6.12.2. United Arab Emirates
 - 15.6.12.3. Qatar
 - 15.6.12.4. Kuwait
 - 15.6.12.5. Oman
 - 15.6.12.6. Bahrain
 - 15.6.12.7. South Africa
 - 15.6.12.8. Egypt
 - 15.6.12.9. Nigeria
 - 15.6.12.10. Morocco
 - 15.6.12.11. Rest of Middle East & Africa

16. COMPETITIVE LANDSCAPE

- 16.1. Competitive Scenario
- 16.2. Market Share Analysis – Global
- 16.3. Market Share Analysis – North America
- 16.4. Market Share Analysis – Latin America
- 16.5. Market Share Analysis - Europe
- 16.6. Market Share Analysis – Asia-Pacific
- 16.7. Market Share Analysis – Middle East and Africa
- 16.8. Mergers and Acquisitions Analysis
- 16.9. Partner Identification Analysis
- 16.10. Investment & Funding Landscape
- 16.11. Strategic Alliances & Innovation Pipeline

17. COMPANY PROFILES

- 17.1. Johnson & Johnson (J&J)*
 - 17.1.1. Company Overview
 - 17.1.2. Product Portfolio and Description
 - 17.1.3. Revenue Analysis
 - 17.1.4. Pricing Analysis
 - 17.1.5. SWOT Analysis
 - 17.1.6. Recent Developments
 - 17.1.6.1. Major Deals
 - 17.1.6.2. M&A
 - 17.1.6.3. Collaboration
 - 17.1.6.4. Acquisition
 - 17.1.6.5. Joint Ventures
 - 17.1.6.6. Innovations
 - 17.1.7. Recent News
 - 17.1.7.1. Events
 - 17.1.7.2. Conferences
 - 17.1.7.3. Symposiums
 - 17.1.7.4. Webinars
- 17.2. F. Hoffmann-La Roche Ltd
- 17.3. Merck & Co., Inc.
- 17.4. Pfizer Inc.
- 17.5. AbbVie Inc.
- 17.6. AstraZeneca
- 17.7. Novartis AG

- 17.8. Bristol-Myers Squibb Company
- 17.9. Lilly USA, LLC
- 17.10. Sanofi
- 17.11. Novo Nordisk A/S
- 17.12. GSK plc
- 17.13. Amgen Inc.
- 17.14. Takeda Pharmaceutical Company Limited
- 17.15. Boehringer Ingelheim International GmbH
- 17.16. Gilead Sciences, Inc.
- 17.17. Bayer AG
- 17.18. Merck KGaA
- 17.19. Teva Pharmaceutical Industries Ltd.
- 17.20. Daiichi Sankyo Company, Ltd.
- 17.21. Biogen (LIST NOT EXHAUSTIVE)

18. APPENDIX

- 18.1. About Us and Services
- 18.2. Contact Us

I would like to order

Product name: Pharmaceuticals Market - 2024-2033

Product link: <https://marketpublishers.com/r/P6DE6028742EEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P6DE6028742EEN.html>